Protalix BioTherapeutics (PLX) Interest Expenses (2013 - 2025)

Protalix BioTherapeutics' Interest Expenses history runs 13 years deep, the most recent figure standing at $6000.0 for Q1 2025.

• In Q1 2025, Interest Expenses fell 98.46% year-over-year to $6000.0; the TTM figure through Dec 2025 stood at $6000.0 (down 99.44% YoY), while the FY2024 annual figure was $1.1 million, down 66.6% from the prior year.
• Interest Expenses was $6000.0 for Q1 2025 at Protalix BioTherapeutics, down from $41000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $2.4 million in Q3 2021 to a low of $6000.0 in Q1 2025.
• Historically, Interest Expenses has averaged $851235.3 across 5 years, with a median of $639000.0 in 2022.
• The sharpest annual moves came in 2023 and 2025: Interest Expenses jumped 109.47% in 2023, then plunged 98.46% in 2025.
• A 5-year view of Interest Expenses shows it stood at $908000.0 in 2021, then declined by 28.41% to $650000.0 in 2022, then advanced by 19.08% to $774000.0 in 2023, then plunged by 94.7% to $41000.0 in 2024, then slumped by 85.37% to $6000.0 in 2025.
• The last three Interest Expenses figures came in at $6000.0 (Q1 2025), $41000.0 (Q4 2024), and $260000.0 (Q3 2024), per Business Quant data.